Land: Kanada
Sprache: Englisch
Quelle: Health Canada
PRAVASTATIN SODIUM
NORA PHARMA INC
C10AA03
PRAVASTATIN
10MG
TABLET
PRAVASTATIN SODIUM 10MG
ORAL
100
Prescription
Active ingredient group (AIG) number: 0122563001; AHFS:
APPROVED
2023-02-22
_Page 1 of 39_ PRODUCT MONOGRAPH Pr NRA-PRAVASTATIN Pravastatin Tablets BP 10 mg, 20 mg and 40 mg pravastatin sodium Lipid Metabolism Regulator Nora Pharma Inc. 1565, boul. Lionel-Boulet Varennes, Quebec J3X 1P7 Date of Preparation: FEB 21, 2023 SUBMISSION CONTROL NO.: 271402 _Page 2 of 39_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 5 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 10 DRUG INTERACTIONS ......................................................................................................... 15 DOSAGE AND ADMINISTRATION ..................................................................................... 17 OVERDOSAGE ........................................................................................................................ 18 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 18 STORAGE AND STABILITY ................................................................................................. 20 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 20 PART II: SCIENTIFIC INFORMATION ............................................................................... 21 PHARMACEUTICAL INFORMATION ................................................................................. 21 CLINICAL TRIALS ............................................................................................... Lesen Sie das vollständige Dokument